Europe Biotechnology Market Size & Outlook, 2024-2030
Europe Biotechnology Market, 2018-2030 (US$M)
Global Market
Related Markets
Europe biotechnology market highlights
- The Europe biotechnology market generated a revenue of USD 480,215.1 million in 2023.
- The market is expected to grow at a CAGR of 13.2% from 2024 to 2030.
- In terms of segment, health was the largest revenue generating application in 2023.
- Bioinformatics is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 480,215.1 million |
| Market revenue in 2030 | USD 1,144,370.4 million |
| Growth rate | 13.2% (CAGR from 2023 to 2030) |
| Largest segment | Health |
| Fastest growing segment | Bioinformatics |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Health, Food & Agriculture, Natural reseources & Environment, Industrial Processing, Bioinformatics, Others Applications |
| Key market players worldwide | AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd |
Other key industry trends
- In terms of revenue, Europe region accounted for 30.9% of the global biotechnology market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 916,391.1 million by 2030.
Europe has witnessed several developments in the field of stem cell research, cell therapy, personalized medicine, biopharmaceutical development, and proteomics. This is because of several initiatives undertaken by the government and nongovernment organizations for development of biotechnology sector in the region.
For instance, the Personalized Medicine 2020 and Beyond initiative included 14 countries and 27 organizations across Europe to enhance research in the area of personalized medicine. In addition, EMA supported the Innovative Medicine Initiative (IMI-2) project to enhance pharmaceutical research in Europe. The project is expected to be completed by 2024.
Similarly, the European Prospective Investigation into Cancer and Nutrition (EPIC) involves 10 countries across Europe to carry out biomarker and genetic investigations for 15 years. The ERA-Net on rare diseases project (E-Rare-3) involves 25 institutions located across 17 non-European, Europe associated, and European countries to study cell- and gene-drug therapy for rare disorders.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biotechnology Market Scope
Biotechnology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
Europe Biotechnology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biotechnology Market Outlook will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 44.43% in 2023.
Horizon Databook has segmented the Europe biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
Europe has witnessed several developments in the field of stem cell research, cell therapy, personalized medicine, biopharmaceutical development, and proteomics. This is because of several initiatives undertaken by the government and nongovernment organizations for development of biotechnology sector in the region.
For instance, the Personalized Medicine 2020 and Beyond initiative included 14 countries and 27 organizations across Europe to enhance research in the area of personalized medicine. In addition, EMA supported the Innovative Medicine Initiative (IMI-2) project to enhance pharmaceutical research in Europe. The project is expected to be completed by 2024.
Similarly, the European Prospective Investigation into Cancer and Nutrition (EPIC) involves 10 countries across Europe to carry out biomarker and genetic investigations for 15 years. The ERA-Net on rare diseases project (E-Rare-3) involves 25 institutions located across 17 non-European, Europe associated, and European countries to study cell- and gene-drug therapy for rare disorders.
- Europe Biotechnology Market Technology Outlook (Revenue, USD Million , 2018-2030)
- Fermentation
- Chromatography Market
- DNA Sequencing
- Cell Based Assay
- Others
- PCR Technology
- Nanobiotechnology
- Tissue engineering and Regeneration
- Europe Biotechnology Market Application Outlook (Revenue, USD Million , 2018-2030)
- Natural reseources & Environment
- Others Applications
- Food & Agriculture
- Health
- Industrial Processing
- Bioinformatics
Reasons to subscribe to Biotechnology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biotechnology Market Outlook databook
- Our clientele includes a mix of Biotechnology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Biotechnology Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Biotechnology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Europe biotechnology market statistics, by technology, 2018-2030 (US$M)
